Clareo Health | Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
With
Kyoto Breast Cancer Research Network
Age
20–75
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. Female patients with histologically or cytologically confirmed breast cancer.
2. Patients with inoperable or recurrent metastatic breast cancer regardless of the metastatic site and number, excluding symptomatic central nervous system metastases.
3. Patients with HER2-negative disease confirmed as ISH negative or IHC 0, 1+ or 2+ (Those with IHC 2+ are eligible, if the additional ISH test results are negative. Those are ineligible who are with any positive results of estrogen receptor or progesterone receptor test on primary and recurrent lesion).
4. Patients who are resistant to hormone therapy.
5. Patients with indication for the first or second line chemotherapy in HER2-negative hormone-resistant inoperable or recurrent metastatic breast cancer who are scheduled to receive the chemotherapy.
6. Patients with the Eastern Cooperative Oncology Group (ECOG) performance status score 0-3 at the time of enrollment.
7. Patients with adequate bone marrow and major organ function judged by the primary physician.
8. Patients who have signed written informed consent to participate in this study.
You may not be if
1. Patients with symptomatic metastasis in the central nervous system.
2. Patients with a previous history of hypersensitivity to any component of drugs which will be administered in the treatment.
3. Patients who are considered to be inappropriate for the study participation by the primary physician.
